All In Biotech

NDA 021845 · Viatris

Revatio

Sildenafil Citrate · Oral

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 3, 2005

Approved uses

5

Original approval plus efficacy supplements

Registered trials

439

87 Phase 3, 20 recruiting

FAERS reports

55,254

38,247 serious, 10,436 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2024.

Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. ( 1 ) Pediatric Patients (1 to 17 years old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise ( 1 , 14 )

Mechanism: Sildenafil is an inhibitor of cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with PAH, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation. Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, greater than 80-fold for...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • REVATIO · SILDENAFIL CITRATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sildenafil" as an intervention, any sponsor and status, largest first.

All 439 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea8,445
  • headache5,765
  • death5,676
  • diarrhoea4,437
  • nausea3,833
  • fatigue3,640
  • dizziness3,413
  • cough3,389
  • pneumonia3,057
  • malaise2,716
  • fluid retention2,314
  • hypotension2,215

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200460
2005120
2006309
2007259
2008493
2009696
20101,588
20112,325
20122,533
20132,825
20145,734
20154,431
20163,367
20174,035
20183,584
20193,653
20203,427
20212,839
20222,721
20232,774
20242,725
20252,704
20262,052

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Revatio (Sildenafil Citrate)

2024 spending

$7.2M

Beneficiaries

100

684 claims

Per beneficiary

$72,205

$58.96 per unit

View as table
YearSpending
2020$9,426,297
2021$8,648,798
2022$8,211,892
2023$7,734,036
2024$7,220,470

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,255 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.